Yazar "Turna, Seval" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    The association of GLUT-1, Galectin 3 and Claudin 1 staining with the type of renal tumors
    (2019) Turna, Seval; Coban, Ganime; Yildiz, Pelin; Unver, Nurcan; Buyukpinarbasili, Nur; Ersoz, Cevper; Gucin, Zuhal
    Aim: The mechanism of carcinogenesis and prognostic parameters of renal cell carcinomas(RCC) exhibiting an increasing incidence trend are still obscure. Even though new tumors types are identified, diagnostic difficulty is even experienced occasionally for the most common tumor types. Various immunohistochemical and molecular-genetic studies are conducted for tumor type identification and prognostic evaluation. The present study examined glucose transporter protein (GLUT-1), galectin-3 that is associated with cell growth, differentiation, proliferation, adhesion, angiogenesis and apoptosis, and Claudin 1, a transmembrane protein of intercellular tight junctions, immunohistochemically for the most commonly encountered renal tumors. The staining patterns were compared in terms of Fuhrman nuclear grade, stage, metastasis, and demographic data. Material and Methods: Methods: The study consisted of a total of 99 renal tumor cases including 40 Clear Cell Renal Cell Carcinoma (CCRCC), 22 Chromophobe Renal Cell Carcinoma (CrRCC), 16 Oncocytoma and 19 Papillary Renal Cell Carcinoma (PRCC) cases. Results: Overexpression of GLUT-1 was observed in 92.5% of CCRCC cases and 36.8% of PRCC cases whereas the loss of expression was observed in CrRCC and Oncocytoma. Claudin-1 was seen in 77.5% of the CCRCCs, 45.4% of the CrRCCs, 81.25% of the oncocytomas and 84.2% of the PRCCs. Galectin-3 was present in 90% of the CCRCCs, 81% of the CrRCCs, 50% of the oncocytomas and 21% of the PRCC Conclusion: Diffuse membranous staining pattern was observed for GLUT-1 in case of CCRCC, however, no correlation with prognostic parameters was noticed. Claudin-1 expression was observed in high nuclear grade tumors. Thus, it may be regarded as a poor prognostic factor. Galectin 3 expression was observed in the tumors with sarcomatoid differentiation.
  • Küçük Resim
    Öğe
    Survivin and Ki-67 expression in leiomyomas, leiomyoma variants, leiomyosarcoma, and STUMP : An immunohistochemical and clinical follow-up study
    (2020) Sonmez, Fatma Cavide; Gokmen Karasu, Ayse Filiz; Turan, Hasan; Comba, Cihan; Turna, Seval
    Aim: Survivin is an “inhibitor of apoptosis” protein. Survivin expression is a poor prognostic factor in a variety of solid tumors. In this clinicopathological study, we aimed to investigate survivin immunostaining of leiomyomas, leiomyoma variants, STUMP (Uterine smooth muscle tumor of uncertain malignant potential)’s and LMS (leiomyosarcoma). Our second objective was to investigate whether survivin immunoreactivity in STUMP and LMS may play a role in determining recurrence.Material and Methods: Consecutive 119 specimens of leiomyoma, leiomyoma variants, STUMP and LMS from the pathology archives of Bezmialem Medical Faculty and Cerrahpasa Medical Faculty were selected. Clinicopathologic characteristics were analyzed and specimens were stained with survivin and Ki-67. The percentage and staining intensity of immunoreactive cells were examined. Additionally, we analyzed whether survivin intensity and expression might be a predictor of LMS recurrence.Results: The patients in the LMS group were older (p 0.001). All LMS and all STUMP specimens were stained with survivin. Survivin staining and Ki-67 staining were highest in the LMS and STUMP groups. Survivin staining was 14.2 ± 6.7 % in the LMS group, 11.2± 10.4 % in the STUMP group, 1.85 ± 1.9 % in the leiomyoma group and 1.4 ± 0.2 % in the leiomyoma variant group (p0.001). Survivin staining intensity was 1.2 ± 0.6 in the LMS group, 0.9 ± 0.2 in the STUMP group, 0.8 ± 0.4 in the leiomyoma group and 0.9 ± 0.3 in the leiomyoma variant group ( p=0.025). Both survivin staining percentage and staining intensity correlated with the Ki-67 proliferation index. In the LMS cases that showed recurrence survivin staining was 16% while in the cases that did not reoccur survivin staining was 2% (p0.001).Conclusion: The antiapoptotic marker “survivin” has not been studied before for smooth muscle tumors of the uterus. Utilizing survivin in conjuncture with histologic features and Ki-67 can also help to determine malignancy potential and LMS recurrence.